Author

R. H. Bortz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Assay:proteomics· 5 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Organism:mouse· 1 Organism:virus· 1

Frequent Co-Authors

K. Chandran· 6 shared R. K. Jangra· 6 shared J. M. Fels· 4 shared A. Mengotto· 3 shared A. S. Herbert· 3 shared A. S. Wirchnianski· 3 shared C. Florez· 3 shared D. Haslwanter· 3 shared

Activity by Year

2018-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

K. Chandran

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants

D. Haslwanter, M. E. Dieterle, A. Z. Wec, C. M. O'Brien, M. Sakharkar, C. Florez, K. Tong, C. G. Rappazzo, G. Lasso, O. Vergnolle, A. S. Wirchnianski, R. H. Bortz, E. Laudermilch, J. M. Fels, A. Mengotto, , R. K. Jangra

This paper identifies NTD-targeting neutralizing antibodies and shows that combining RBD and NTD antibodies reduces the emergence of neutralization-escape mutants.

mBio · Oct 26, 2021Peer-reviewedMicrobiology

A glycoprotein mutation that emerged during the 2013-2016 Ebola virus epidemic alters proteolysis and accelerates membrane fusion

J. M. Fels, R. H. Bortz, T. P. Alkutkar, E. Mittler, R. K. Jangra, J. S. Spence, K. Chandran

This paper investigates how the A82V mutation in the Ebola virus glycoprotein enhances infectivity by altering proteolysis and accelerating membrane fusion.

mBio · Feb 23, 2021Peer-reviewedMicrobiology

Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis

N. G. Herrera, N. C. Morano, A. Celikgil, G. I. Georgiev, R. J. Malonis, J. H. Lee, K. Tong, O. Vergnolle, A. B. Massimi, L. Y. Yen, A. J. Noble, M. Kopylov, J. B. Bonanno, S. C. Garrett-Thomson, D. B. Hayes, , S. C. Almo

This study evaluates the production, characterization, and antigenicity of SARS-CoV-2 S protein constructs in two cell lines, showing high-quality yields and consistent behavior across assays.

bioRxiv · Jun 14, 2020Biochemistry

A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition

M. E. Dieterle, D. Haslwanter, R. H. Bortz, A. S. Wirchnianski, G. Lasso, O. Vergnolle, S. A. Abbasi, J. M. Fels, E. Laudermilch, C. Florez, A. Mengotto, D. Kimmel, R. J. Malonis, G. Georgiev, J. Quiroz, , R. K. Jangra

This paper develops a recombinant vesicular stomatitis virus expressing SARS-CoV-2 spike protein to assess neutralizing antibodies in convalescent sera and validate its utility for vaccine and therapeutic development.

bioRxiv · May 20, 2020Microbiology

A virion-based assay for glycoprotein thermostability reveals key determinants of filovirus entry and its inhibition

R. H. Bortz, A. C. Wong, M. G. Grodus, H. Recht, M. C. Pulanco, G. Lasso, S. J. Anthony, E. Mittler, R. K. Jangra, K. Chandran

This paper introduces an ELISA-based assay to measure the thermostability of filovirus glycoproteins, revealing how proteolytic cleavage, acid pH, and small-molecule inhibitors affect GP stability and viral entry.

bioRxiv · Feb 25, 2020Microbiology

Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protection

A. Z. Wec, Z. A. Bornholdt, S. He, A. S. Herbert, E. Goodwin, A. S. Wirchnianski, B. M. Gunn, Z. Zhang, W. Zhu, G. Liu, D. M. Abelson, C. L. Moyer, R. K. Jangra, R. M. James, R. R. Bakken, , K. Chandran

This paper develops a human antibody cocktail, MBP134, that provides broad protection against multiple ebolaviruses, showing enhanced efficacy in guinea pigs compared to individual antibodies.

bioRxiv · Aug 20, 2018Microbiology